Negative results associated with medicines and quality of life in multiple sclerosis

Increased morbimortality related to non-transmissible diseases and pharmacotherapy required a new attitude of the pharmacist and greater involvement in the prevention of negative clinical outcomes associated with the use (or non-use) medicines. For patients with chronic diseases such as multiple sclerosis (MS), the influence of treatment on quality of life (QOL) is acrucial determinant during therapy. The aim of the study was to identify the impact of NRM on QL of MS patients. Method: Cross-sectional, descriptive and analytical study of MS patients. In this study was used data from the clinical interview, computerized system, medical records and patient health documents. The NRM were identified and evaluated by the investigator. QOL was determined by the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). Results: Eighty-onepatients with MS participated in the study. All patients presented at least 01 NRM, mean of 03 NRM per patient (ranging from 01 to 04). A total of 354 NRM was identified. Regarding QOL, results were observed with below-desirable averages in all domains, with the domain “physical limitations” being the lowest average while “social aspects” being the highest average. Regarding QOL, results were observed with below-desirable averages in all domains, with the domain “physical limitations” being the lowest average while “social aspects” being the highest average. Bivariate analysis of the NRM quantitative and its influence on patients' quality of life showed a significant correlation with all domains of the physical and mental component (Spearman's linear correlation test, p <0.005). Conclusions: The NRM impacted the QOL of the patients, evidencing the need to assure better conditions of care and follow-up of the NRM in MS patients.